PSMD8 promotes breast cancer progression and attenuates paclitaxel sensitivity by stabilizing KIF10 Authors: Chenyuan Li, Xinyue Nie, Shichong Liao, Feng Yao Published: 2026 ABSTRACT AbstractBackgroundBreast cancer (BC) patients have been threatened by distant metastasis and variations in treatment response for a long time. The mechanism urgently remains to be explored.MethodsBioinformatics analysis were performed to indicate the expression and function of related markers, and verified in BC tissues as well as adjacent tissues. Functional assays employed in vitro and in vivo with PSMD8 knockdown or overexpression. Mechanistic studies evaluated the ubiquitination degradation process via co-immunoprecipitation and rescue experiments.ResultsIn the present study, PSMD8 was abnormally upregulated in BC tissues compared with adjacent tissues and was related to poor prognosis in BC patients. The knockdown of PSMD8 attenuated the biological effect and EMT progression in vitro and in vivo and augmented the sensitivity of BC cells to paclitaxel, whereas PSMD8 overexpression showed the opposite effects. Mechanistic analysis indicated that PSMD8 stabilized KIF10, and we observed its tumor-promoting effect in BC tumor cells. Moreover, KIF10 knockdown significantly antagonized the facilitating effect of PSMD8 on the EMT program and response to paclitaxel treatment. Finally, the PSMD8/KIF10 axis activated the ERK pathway. Inhibiting the ERK pathway in PSMD8-overexpressing cell lines partially blocked EMT progression and altered the cellular response to paclitaxel.ConclusionIn conclusion, our results demonstrated that the PSMD8/KIF10 axis promoted BC development and modulated paclitaxel sensitivity via the ERK pathway. Our findings provide a theoretical basis for targeting PSMD8 to BC cells as a novel target for the treatment of BC.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12935-026-04382-4.Keywords: Breast cancer, PSMD8, KIF10, EMT, ERK pathway Introduction Breast cancer (BC) is the most common malignant carcinoma and the leading cause of cancer death among women [1]. The increased occurrence rate of metastasis exacerbates the mortality rate in BC. The 5-year overall survival rate without metastasis is over 80%, while distant metastasis reduces this rate to 25% [2, 3]. Moreover, variations in treatment response can further impact survival. Hence, searching for new therapeutic targets is necessary. The 26 S proteasome is an adenosine triphosphate (ATP)-dependent protease associated with protein degradation and conjugated with multiple ubiquitins [4]. The proteasome 26 S subunit, non-ATPase 8 (PSMD8, also known as RPN12), is one of the components of the 19 S regulator of the 26 S proteasome [5]. The free PSMD8 subunit binding to the other eight subunits assembles the lid subcomplex of the 19 S regulatory particle [6]. The latest research revealed a PSMD8 mutation in diffuse large B-cell lymphoma [7]. More importantly, PSMD8 was significantly overexpressed in bladder urothelial carcinoma and predicted poor overall survival (OS) and progression-free survival (PFS) [8]. A previous study demonstrated that PSMD8 was highly expressed in BC [9]; however, further exploration of the potential mechanism by which PSMD8 affects BC progression has not yet been reported. The kinesin superfamily (KIFs) is characterized by microtubule-based motors. They function as intracellular transporters along microtubules in an ATP-dependent manner [10]. Forty-five KIFs have been discovered and illustrated to have different tumor pathobiologies [11]. KIF10 is localized on unattached kinetochores during mitosis and slides chromosomes to the spindle equator [12]. In the latest studies, KIF10 was reported to favor tumor initiation, development, and progression [13]. KIF10 was found to be upregulated in BC and hepatocellular carcinoma and was correlated with worse prognosis [13, 14]. In estrogen receptor (ER)-positive BC, estrogen strongly induces KIF10 expression [15]. However, its underlying mechanism remains elusive. In this study, we identified the PSMD8/KIF10 axis as a novel therapeutic target in BC progression, and demonstrated its potential for modulating paclitaxel sensitivity. Materials and methods Data acquisition The expression of PSMD8 and KIF10 and their relationship with BC prognosis were analyzed by the UALCAN (http://ualcan.path.uab.edu) and GEPIA (http://gepia.cancer-pku.cn/) databases and Kaplan–Meier Plotter (https://kmplot.com/). Their mRNA profiling data were obtained from The Cancer Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.gov/tcga/) and GEO database. Cell culture and reagents The human breast cancer cell lines MDA-MB-231 and MCF-7 were obtained from the American Type Culture Collection. Cells were cultured with Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS) and 1% penicillin‒streptomycin at 37 °C. U0126 (HY-12031) was purchased from MedChemExpress and dissolved in DMSO. siRNAs and plasmid transfection PSMD8 siRNA (5’- GCAGGGCACGAGTTATTTAAA), KIF10 siRNA (5’- GCUACUAAAUCAGGAGAAUTT), and scramble siRNA were purchased from GenePharma. Flag-PSMD8 and Flag-NC were purchased from GeneChem Co. Lipofectamine 2000 (Invitrogen, USA), and reduced serum medium (Opti-MEM, Gibco) were used according to the instructions. Human PSMD8 shRNA and control shRNA lentiviruses were obtained from GeneChem Co. Immunohistochemistry (IHC) IHC was performed to examine the expression of PSMD8, KIF10, E-cadherin, Snail, and Ki67. The scoring methods were described in a previous study [16]. All samples were categorized as negative, low expression or high expression according to the score. Breast cancer tissues and normal breast tissues were collected at Renmin Hospital of Wuhan University. All procedures performed in this study were approved by the Ethics Committee of Renmin Hospital of Wuhan University (No.: 20133655893). Immunofluorescence (IF) Treated cells were fixed with 4% paraformaldehyde at room temperature and permeabilized with 0.2% Triton-X 100 for 15 min at 4 °C. BSA (2%) was prepared for blocking for 1 h at room temperature. The primary antibody was prepared with 1% BSA. Cells were incubated with the corresponding primary antibody overnight at 4 °C and then 488-conjugated (Invitrogen, A-11034) and 568-conjugated (Invitrogen, A-11011) secondary antibodies for 30 min at room temperature. All samples were stained with DAPI for 3 min. Fluorescence images were obtained by fluorescence microscopy. Western blotting (WB) The WB procedure was performed as described previously [17]. The membrane was blocked in 5% fat-free milk for 2 h at room temperature and incubated with primary antibody overnight at 4 °C. Finally, the membranes were incubated with secondary antibodies for 1 h at room temperature. All antibodies are listed in Supplementary Table. RNA extraction and quantitative real-time PCR Total RNA was isolated by TRIzol reagent. Reverse transcription was performed using a TransScript First-Strand cDNA Synthesis Kit (TaKaRa, Japan) according to the manufacturer’s instructions. The primers for KIF10 (forward: 5’-CCTTAACTTGTGGAGGTGGC) and PSMD8 (forward: 5’-GCCGTAAATCAGGCGGTCT) were used. qRT‒PCR was carried out by SYBR Green MasterMix (TaKaRa, Japan). In vivo deubiquitination assay Total proteins were extracted in np-40 lysis buffer. The lysates were incubated with the anti-KIF10 antibody and protein G agarose beads at 4 °C overnight. The beads were collected for WB analysis. Cell Counting Kit-8 assay (CCK8) Two thousand treated cells were seeded on a 96-well plate. Ten microliters of CCK8 (CK04, Dojindo, Japan) solution was added to each well. After 2 h of incubation, the absorbance was determined at 450 nm. Transwell assay Treated cells were seeded in the upper chambers with Matrigel in serum-free medium, and DMEM with 10% FBS was added to the lower chamber. Cells were cultured for 24 h, fixed, and stained with 0.1% crystal violet. Flow cytometry (FCM) After a series of treatments, the cells were washed with PBS and digested with non-EDTA trypsin enzyme. Cells were suspended in culture medium and centrifuged at 1,000 rpm for 5 min. The supernatant was discarded, and the cells were resuspended in PBS and centrifuged at 1,000 rpm for 5 min again. Double staining with Annexin V-FITC and propidium iodide (PI) (Biouniquer, BU-AP0103) was performed and the cells were incubated for 15 min. The results were determined by FCMcan flow cytometry (FASC Calibur, BD, USA). Animal experiments MDA-MB-231 cells were infected with LV-shPSMD8 and LV-shCtrl lentiviruses (GeneChem Co., Shanghai, China). A total of 2.5 × 106 cells per mouse were inoculated into the right iliac fossa of 4-week-old female BALB/c nude mice. After 15 days of feeding, the mice were sacrificed, and the xenografts were separated for further analysis. Similarly, LV-shPSMD8 and LV-shCtrl cells were also injected into the fourth mammary fat pad (1 × 106 cells per mouse). When the tumor size reached approximately 300 mm3, the tumors were removed, and the mice were sacrificed 10 days after the operation. The lung tissues were separated and fixed. Hematoxylin and eosin (HE) staining was performed to demonstrate lung metastasis. The animal experiment was approved by the Laboratory Animal Welfare & Ethics Committee, Renmin Hospital of Wuhan University, in compliance with Institutional Animal Care and Use Committee guidelines for the care and use of animals (No.: 20180915). Statistical analysis Data were analyzed by one-way ANOVA with SPSS 22.0. The graphs were made by GraphPad Prism 6. Independent experiments were repeated at least three times. P < 0.05 indicated statistical significance. Results PSMD8 promoted cell growth and invasion in vitro Data from GEPIA and UALCAN showed that PSMD8 expression in breast cancer was significantly upregulated in tumor tissue compared with adjacent tissue, similarly with the results of IHC staining (Supplementary Fig. 1A-F). And high level of PSMD8 predicted the worse survival (Supplementary Fig. 1G-I). To explore the effect of PSMD8 on the biological behavior of MDA-MB-231 and MCF-7 breast cancer cell lines, we used PSMD8 siRNA and plasmids to downregulate and upregulate the expression level of PSMD8 in cells, respectively. We first displayed the efficiency of PSMD8 knockdown (KD) and overexpression (OE) (Fig. 1A and D). A CCK-8 assay was performed to test tumor proliferation after the corresponding treatments. PSMD8 knockdown attenuated tumor growth, while PSMD8 overexpression enhanced tumor growth (Fig. 1B and E). In addition, cell invasion was also decreased as PSMD8 was knocked down and increased as PSMD8 was overexpressed (Fig. 1C and F). In brief, PSMD8 promoted proliferation and invasion in BC cells. PSMD8 promoted cell proliferation and a prometastatic phenotype in BC cells. (A, D) Knockdown and overexpression efficiency of PSMD8 in MDA-MB-231 and MCF-7 cell lines. (B, E) CCK-8 assay performed in knockdown and overexpressed cell lines. (C, F) Transwell assays performed in knockdown and overexpressed cell lines (magnification 200×). The values are presented as the means ± SDs from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the control group PSMD8 triggered the EMT program in BC cells Given the correlation between EMT and tumor development, we further explored the role of PSMD8 in EMT progression. We knocked down the expression of PSMD8 and detected the protein levels of the EMT-related proteins E-cadherin (E-cad), N-cadherin (N-cad), Vimentin and Snail. The WB results showed that the level of E-cad was upregulated, whereas N-cad, Vimentin and Snail were downregulated in PSMD8KD cells. The opposite results were observed in PSMD8OE cells (Fig. 2A-B). In parallel, IF pictures confirmed this phenomenon (Fig. 2C). In addition, the results of IHC indicated that PSMD8 and E-cad expression were inversely correlated (Fig. 2D). Furthermore, the WB results illustrated that PSMD8 overexpression reversed the effect of PSMD8 knockdown (Fig. 2E). In summary, PSMD8 promoted EMT progression in vitro. PSMD8 promoted EMT progression. (A-B) EMT-related protein levels in PSMD8-knockdown and PSMD8-overexpressing cell lines. (C) IF images of PSMD8 and EMT-related markers (E-cad and Snail) in BC cell lines (magnification 630×). (D) IHC staining images of PSMD8 and E-cad in BC samples (scale=20 μm, magnification 400×). (E) PSMD8 was overexpressed in PSMD8KD cells. WB analysis measured EMT-related protein levels. The values are presented as the means ± SDs from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the control group Inhibition of PSMD8 suppressed tumor growth and lung metastasis in vivo We established xenograft models to verify the effect of PSMD8 in vivo. First, LV-shPSMD8 was applied to MDA-MB-231 cells to establish stably silenced cells (Fig. 3A-B). A photograph of xenografts is displayed (Fig. 3C), and their weights were compared. The mean weight of the shPSMD8 group was significantly less than that of its counterpart (Fig. 3D). Inhibition of PSMD8 suppressed tumor growth and metastasis in vivo. (A) Infection efficiency of stable PSMD8 knockdown in MDA-MB-231 cells by fluorescence microscopy. (B) Infection efficiency of PSMD8 knockdown in MDA-MB-231 cells by WB. (C) Tumors dissected from various groups of mice. (D) Tumor weight from various groups of mice. (E) Bright field images of lung metastasis in the control group and knockdown group (left panel). The number of lung metastatic foci was quantified (right panel). (F) HE staining of metastatic lung tumors (scale=20 μm). (G) IHC staining of PSMD8, Ki67 and E-cad in xenografts from various groups (scale=20 μm). The values are presented as the means ± SDs from three independent experiments. **p < 0.01, and ***p < 0.001 compared with the control group Additionally, we infected mice with the treated cells in situ and measured lung metastasis. The separated lung tissue showed that the number of lung metastatic nodules was lower in the shPSMD8 group (Fig. 3E). HE staining demonstrated the same trend (Fig. 3F). In addition, we detected the levels of Ki67 and E-cad in tumors removed from xenograft models. IHC staining showed that E-cad expression increased, while the expression of Ki67 decreased after PSMD8 was silenced (Fig. 3G). In summary, this phenomenon suggested that silencing PSMD8 impaired the growth of breast tumors and decreased lung metastasis. PSMD8 stabilized the KIF10 protein To verify the underlying mechanism of PSMD8 on BC progression, we detected the protein level of KIF10 in PSMD8KD and PSMD8OE cells. The WB results showed that the protein level of KIF10 was decreased after PSMD8 knockdown and increased after PSMD8 overexpression (Fig. 4A). Parallel effects were observed in BC patient tissues by IHC staining (Fig. 4B). Additionally, the protein levels of PSMD8 and KIF10 in xenografts were detected by IHC, which illustrated that the level of KIF10 was decreased in the shPSMD8 group compared with the shCtrl group (Fig. 4C). Thus, we next investigated how PSMD8 affected the expression of KIF10. The mRNA level of KIF10 did not change after downregulation and upregulation of PSMD8 (Fig. 4D), indicating that PSMD8 modulated KIF10 expression through a posttranscriptional mechanism. Therefore, a ubiquitination assay was performed and validated that the ubiquitination level of KIF10 was significantly increased by PSMD8 deficiency (Fig. 4E). Furthermore, After K48-mutation treatment, the ubiquitination of KIF10 markedly attenuated, whereas K63-mutation treatment remained unaltered compared with PSMD8-knockdown alone. Meanwhile, K48 mutation, rather than K63 mutation, resulted in the accumulation of KIF10 protein (Fig. 4E). We also checked the effect of both PSMD8 knockdown and overexpression on the stability of endogenous KIF10 protein by performing a cycloheximide (CHX) pulse-chase assay. It was showed that PSMD8 interference accelerated the degradation of KIF10 protein, whereas PSMD8 overexpression strikingly extended the half-life of KIF10 protein levels (Fig. 4F-G). More importantly, K-M analysis showed that the prognosis of BC patients with high levels of both PSMD8 and KIF10 was worse than that with low levels of both PSMD8 and KIF10 in the GES1456 database (Fig. 4H). Overall, the stability of KIF10 was regulated by PSMD8 and was positively correlated. PSMD8 stabilized KIF10 expression. (A) KIF10 expression was measured by WB in PSMD8-knockdown and PSMD8-overexpressing cells. (B) IHC staining images of PSMD8 and KIF10 in BC samples (scale=20 μm, magnification 400×). (C) IHC staining of PSMD8 and KIF10 in xenografts. The values are presented as the means ± SDs from three independent experiments (scale=20 μm, magnification 400×). (D) Expression of KIF10 mRNA in PSMD8-downregulated and PSMD8-upregulated cells compared with their counterparts. (E) PSMD8 was knocked down in MDA-MB-231 and MCF-7 cells, with or without either K48- or K63-mutation. The corresponding groups of cells were treated with 10 µM MG132 for 24 h. The cell lysates were then immunoprecipitated with anti-KIF10 antibody, and the immunocomplexes were immunoblotted with anti-ubiquitin antibodies. (F-G) Control and PSMD8 knockdown cells were treated with CHX (100 µg/mL) for the indicated time points. The cell lysates were subjected to immunoblotting (left panel), and KIF10 expression was quantified (right panel). (H) K-M analysis of BC patients with different PSMD8 and KIF10 expression. The values are presented as the means ± SDs from three independent experiments. *p < 0.05 and ***p < 0.001 compared with the corresponding group KIF10 knockdown decreased cell growth and invasion in vitro Similar to PSMD8, KIF10 also shows high expression in breast cancer tissues and is associated with poor prognosis (Supplementary Fig. 2). We next explored the exact effect of KIF10 on the biological functions of BC cells. The knockdown efficiency of KIF10 in BC cells is shown in Fig. 5A. The results of CCK-8 and Transwell assays demonstrated that cell proliferation ability and the ratio of cell invasion were decreased after KIF10 knockdown (Fig. 5B-C). In addition, the WB results showed that the expression level of E-cad was increased, while the level of N-cad, Vimentin and Snail were decreased in KIF10-knockdown cells (Fig. 5D). Furthermore, the expression of PSMD8 was positively correlated with the expression of KIF10 (Fig. 5E). These results suggested that KIF10 was capable of impairing tumor progression. Knockdown of KIF10 attenuated cell proliferation and the pro-metastatic phenotype in BC cells. (A) Knockdown efficiency of KIF10 in MDA-MB-231 and MCF-7 cell lines. (B) CCK-8 assay performed in KIF10 knockdown cell lines. (C) Transwell assay performed in KIF10 knockdown cell lines (magnification 200×). (D) EMT-related protein levels in KIF10-knockdown cell lines. (E) IHC staining images of PSMD8 and E-cad in BC samples (magnification 400×). The values are presented as the means ± SDs from three independent experiments. **p < 0.01 and ***p < 0.001 compared with the corresponding group The PSMD8/KIF10 axis promoted tumor development via ERK pathway in vitro Given that both PSMD8 and KIF10 promoted tumor development and that these two had a positive correlation, we further verified their link and effect that KIF10 deficiency significantly reversed the effect of PSMD8 overexpression on EMT process (Fig. 6A-C). In summary, the PSMD8-KIF10 axis could enhance EMT progression. The PSMD8/KIF10/ERK axis promoted BC progression in vitro. (A) CCK8 assay performed in PSMD8OE+KIF10KD cells. (B) Transwell assay performed in PSMD8OE+KIF10KD cells. (magnification 200×). (C) EMT-related protein levels in PSMD8OE+KIF10KD cells. (D) p-ERK and ERK levels measured by WB in PSMD8KD and KIF10KD cells, respectively. (E) p-ERK and ERK levels measured by WB in PSMD8OE+KIF10KD cells. (F) CCK-8 assay performed in PSMD8OE cells treated with 20 µM U0126 for 24 h. (G) Transwell assay performed in PSMD8OE cells treated with 20 µM U0126 for 24 h. (magnification 200×). (H) Cells were treated as above. WB was performed to detect the protein levels of EMT-related markers. The values are presented as the means ± SDs from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the corresponding group Furthermore, the ratio of p-ERK/ERK significantly decreased in both PSMD8KD and KIF10KD cells (Fig. 6D), PSMD8 overexpression significantly enhanced ERK pathway activation, whereas KIF10 knockdown in PSMD8-overexpressing cells reversed this effect, as reflected by the reduced p-ERK/ERK ratio (Fig. 6E). In addition, the ratio of p-ERK/ERK returned after the knockdown of KIF10 in PSMD8OE cells (Fig. 6E). Moreover, the rescue experiments suggested (Fig. 6F-H) that the ERK signaling was involved in PSMD8/KIF10 axis regulated EMT progression. Finally, considering the application prospects of PSMD8 in breast cancer treatment, further exploration illustrated that PSMD8 significantly inhibits the killing effect of PTX on tumor cells through the KIF10/ERK axis (Supplementary Fig. 3). Discussion Due to the aggressive threat of BC, the search for new therapeutic targets is urgent. In this study, we found that PSMD8 was highly expressed in tumor tissue and was associated with poor survival in BC patients. Experiments performed in vitro and in vivo verified that PSMD8 could enhance cell viability, invasion and EMT progression. Further exploration revealed the underlying mechanism by which PSMD8 stabilized KIF10, thus activating the ERK signaling pathway. Finally, the PSMD8/KIF10/ERK axis affected the apoptotic response of BC cells to PTX treatment. Therefore, PSMD8 could be a novel therapeutic target for BC. The 26 S proteasome is the endpoint for the ubiquitin‒proteasome system, the function of which ranges from protein homeostasis to cellular processes such as signal transduction and stress responses [18]. PSMD8 was reported to be overexpressed in BC tissues [9], consistent with our results. However, almost no study has demonstrated the effect and mechanism of PSMD8 in tumor development. As a structural component of the proteasome, we inferred that PSMD8 should have a similar function to other subunits. For example, PSMD14 promotes tumor growth and metastasis in gliomas [19], hepatocellular carcinoma [20], and esophageal squamous cell carcinoma [21]. Its contributions to tumorigenesis and altered chemotherapy response were also observed in colorectal cancers [22]. Obviously, cell growth and invasion were enhanced after PSMD8 overexpression in our report. Moreover, the results of FCM verified the increased sensitivity to PTX after knocking down the expression of PSMD8. In addition, mass spectrometry to examine the interaction between Snail and deubiquitinases illustrated that PSMD14 targeted Snail for deubiquitination and stabilization, thus mediating Snail-induced EMT [21]. In this study, we measured the expression of Snail after PSMD8 interference and overexpression. The results illustrated that PSMD8 favored the expression of Snail and EMT progression. The kinesin family is essential for mitosis and chromosome alignment [12]. It is likely that KIF10 is related to cell proliferation. Thus, we provided evidence that KIF10 was involved in cell growth in vitro and in vivo. KIF10 was overexpressed in BC and hepatocellular carcinoma and was associated with worse OS, RFS, and distant metastasis-free survival [13, 14]. However, only bioinformatics analysis was provided to support these perspectives. The results of our study further verified this hypothesis. IHC staining and WB illustrated that KIF10 was highly expressed in tumor tissues. Moreover, knocking down KIF10 significantly reduced the proliferation rate, invasion ability, and EMT process of BC cells. Furthermore, KIF10 was stabilized by PSMD8 and was thereby involved in PSMD8-regulated BC development. Considering the tumor-promoting effect of KIF10 and its elusive degradation pattern, we revealed the mechanism underlying PSMD8-mediated KIF10 regulation. We found a positive correlation between the protein level of PSMD8 and KIF10 but no correlation between their mRNA levels. It was reported that PSMD8 is an essential component of the 19 S regulatory particle. Thus, we measured the degradation level of KIF10 after PSMD8 regulation. Moreover, the knockdown of PSMD8 accelerated the degradation of the KIF10 protein, whereas PSMD8 overexpression dramatically prolonged the half-life of the KIF10 protein. Additionally, the ubiquitination level of KIF10 was significantly increased by depletion of PSMD8. However, existing evidence indicates that PSMD8 serves as a structural module in the proteasome, and PSMD8-mediated ubiquitination of KIF10 might be indirect. The exact molecular mechanism warrants further investigation. ERK is an evolutionarily conserved signaling pathway that transmits information from the cell surface to promote cell proliferation and survival. Dysregulation of the ERK pathway is involved in the induction of primary cancer [23]. Hyperexpression of ERK activated the antiapoptotic molecule BCL2 in BC, resulting in drug resistance [24]. In our study, the ERK pathway was regulated by both PSMD8 and KIF10. Moreover, KIF10 interference in PSMD8OE cells inhibited the ERK pathway, implying that the regulation of the ERK pathway by PSMD8 partially depended on KIF10 expression. A few studies hint at this possibility. ERK signaling was reported to control the G1/S phase of the cell cycle in proliferating cells [25]. The activation of ERK induced the response to mitogens [26], which suggested its link with KIF10 and its proliferative effect. Considering the modulation of the ERK pathway by PSMD8 and the promoting effect of the ERK signaling pathway on BC development, PSMD8 played an important role in promoting BC progression and inhibiting tumor apoptosis via the upregulation of KIF10 and the involvement of the ERK pathway. One limitation of this study is that deeper mechanistic insight into how PSMD8 regulates KIF10 ubiquitination remains unclear. PSMD8 deubiquitylates the KIF10 protein; however, there is a lack of evidence to explain whether PSMD8 itself has a deubiquitination function or whether some other deubiquitinase is involved. Additionally, how KIF10 regulates the ERK pathway needs further exploration. We speculate that ERK may be phosphorylated by KIF10 in an indirect manner. In conclusion, we identified PSMD8 as a tumor promoter and initially explored its mechanism. PSMD8 stabilized the KIF10 protein, thereby activating the ERK pathway and consequently favoring tumor progression and altered sensitivity to paclitaxel treatment. The results of this research clarify that the PSMD8/KIF10 axis plays a vital role in the progression of BC and provide novel potential therapeutic targets for the precise treatment of BC. Supplementary Information Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements A previous version of this work was posted on the preprint server under the title “PSMD8 Promotes Breast Cancer Progression and Attenuates Paclitaxel Sensitivity by Regulating the Expression of KIF10” (DOI: https://doi.org/10.21203/rs.3.rs-859898/v1). Author contributions LS and YF contributed to the experimental design; LC and LJ contributed to the acquisition of data and the drafting of manuscript; NX contributed to the data analysis. All authors have read and approved the final manuscript. Funding This work was supported by the China Postdoctoral Science Foundation (No. 2025M772081) to Chenyuan Li. Data availability The datasets generated and analyzed during the current study are available in the UALCAN ( [http://ualcan.path.uab.edu](http:/ualcan.path.uab.edu) ), GEPIA (http://gepia.cancer-pku.cn/), Kaplan–Meier Plotter ( [https://kmplot.com/](https:/kmplot.com) ), The Cancer Genome Atlas (TCGA) ( [https://tcga-data.nci.nih.gov/tcga/](https:/tcga-data.nci.nih.gov/tcga) ) and GEO databases. Declarations Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Shichong Liao, Email: liaoscwhu@163.com. Feng Yao, Email: yaofengrmh@163.com. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement The datasets generated and analyzed during the current study are available in the UALCAN ( [http://ualcan.path.uab.edu](http:/ualcan.path.uab.edu) ), GEPIA (http://gepia.cancer-pku.cn/), Kaplan–Meier Plotter ( [https://kmplot.com/](https:/kmplot.com) ), The Cancer Genome Atlas (TCGA) ( [https://tcga-data.nci.nih.gov/tcga/](https:/tcga-data.nci.nih.gov/tcga) ) and GEO databases.